Top News
LIBRETTO-121: A Phase 1/2 Trial Investigating LOXO-292 in Pediatric Patients With Advanced Solid or Primary CNS Tumors
Phase 1/2 Study of Durvalumab and Tremelimumab in Pediatric Cancer
Clinical Trial Assesses Combination Chemotherapy With or Without Temsirolimus for Intermediate-Risk Rhabdomyosarcoma
Trial to Assess Brentuximab Vedotin With Adriamycin, Vinblastine, and Dacarbazine in Pediatric Patients With Hodgkin Lymphoma
The Role of Direct Oral Anticoagulants in the Outpatient Setting Questioned
Breastfeeding Duration May Influence Markers of Inflammation and Proliferation in Breast Tissue of Healthy Parous Women
Active Surveillance for Intermediate-Risk PCa Increasing in US
Nonchromosomal Birth Defects May Up Childhood Cancer Risk
Drug Combo Slows Progression in Advanced Breast Cancer
EDITORIAL ADVISORY BOARD
E. David Crawford, MD
Jeffrey M. Farma, MD
Featured
-
Analysis Sheds Light on Bevacizumab “Reversals” in Glioblastoma
Improvements to PFS and “clinically meaningful reductions in daily corticosteroid use” were said to be linked to the addition of bevacizumab in glioblastoma. -
Multidisciplinary Genetic Tumor Boards: Critical for Interpreting Tumor-Only Sequencing Results
One approach for improving recommendations based on tumor-only sequencing is use of a multidisciplinary genomic tumor board, in which researchers from a variety of backgrounds weigh in on the best way to interpret test results. -
A Glossary of Cancer Terms for Patients
This fact sheet provides the meaning of oncology lingo that patients may commonly hear following a cancer diagnosis. -
The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma
Updated guidelines advised against performing cytoreductive nephrectomy in poor-risk patients. -
Tumors With High Levels of Microsatellite Instability Responded Well to Treatment With PD-1 Inhibitors
New research has linked microsatellite instability and the number of insertion/deletion mutations present in a tumor to clinical response to checkpoint inhibition. -
Research Shows How Talc Powder May Change Ovarian Cancer Cells
Prospective studies on talc and cancer are necessary to fully form our collective understanding of talc’s risks.
More Features
The Evolution of Frontline Hodgkin Lymphoma Treatment
With numerous options, there is growing debate over the frontline treatment of Hodgkin lymphoma.
Emerging Pomalidomide-Based Triplet Therapies for Multiple Myeloma
Pomalidomide-based triplet therapies appear safe, effective, and associated with improved outcomes compared with the current standard of care.
Evaluating the Cost-Effectiveness of Acute Myeloid Leukemia Treatment
The approval of novel oral therapeutic agents may offer a more cost-effective treatment option for acute myeloid leukemia.
The Revival of a Forgotten Cancer Gene Therapy With Off-the-Shelf Potential
A universal cancer gene therapy from the early 2000s is headed into phase 2 trials, in light of renewed interest and outlier patients who are still alive at 10 years later.
Looking Back to Go Forward: CAR-T Cell Therapy in R/R CLL
Research suggests that ibrutinib may have the ability to alter the phenotype of a final CAR-T cell product.
